CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Get Free Report) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 4,800 shares, a drop of 25.0% from the February 13th total of 6,400 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 8,600 shares, the days-to-cover ratio is presently 0.6 days.
CollPlant Biotechnologies Trading Up 3.5 %
Shares of CollPlant Biotechnologies stock opened at $3.27 on Friday. CollPlant Biotechnologies has a 12 month low of $3.00 and a 12 month high of $6.75. The firm has a market capitalization of $37.46 million, a P/E ratio of -2.12 and a beta of 1.07. The business has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $4.09.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. Benjamin Edwards Inc. purchased a new position in shares of CollPlant Biotechnologies during the third quarter valued at approximately $112,000. AMH Equity Ltd raised its stake in CollPlant Biotechnologies by 17.4% during the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after buying an additional 17,295 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in CollPlant Biotechnologies by 110.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after acquiring an additional 4,405 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new position in shares of CollPlant Biotechnologies during the fourth quarter valued at $38,000. 21.69% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on CollPlant Biotechnologies
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
Featured Stories
- Five stocks we like better than CollPlant Biotechnologies
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- The Significance of Brokerage Rankings in Stock Selection
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Use the MarketBeat Stock Screener
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.